Sparrow Clinical Research Institute | Sparrow Hospital - Clinical Research Department

Research site

Site insights

Top conditions

Top treatments

Diazoxide Choline

Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 63 total trials

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Set...

Patent Foramen Ovale
Device: AMPLATZER™ PFO Occluder

The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN®...

Active, not recruiting
Device: WATCHMAN Left Atrial Appendage Closure
Device: Amulet Left Atrial Appendage Occluder

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Lead...

Active, not recruiting
Cardiac Rhythm Disorder
Device: Aveir DR Leadless Pacemaker System

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of...

Active, not recruiting
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Drug: Placebo tadalafil
Drug: Macitentan 10 mg

The AMPLATZER Muscular VSD Occluder was approved by the US Food and Drug Administration (FDA) in September, 2007. This study is designed to further e...

Active, not recruiting
Ventricular Septal Defects
Device: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)

The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to plac...

Community-acquired Pneumonia
Drug: Trimodulin
Drug: Placebo (human albumin 1%)

To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.

Active, not recruiting
Percutaneous Coronary Revascularization
Other: Placebo
Drug: FDY-5301

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipi...

Active, not recruiting
Myocardial Infarction
Drug: Evolocumab
Drug: Routine Lipid Management

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi...

Active, not recruiting
Prader-Willi Syndrome
Drug: DCCR

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aorti...

Active, not recruiting
Symptomatic Severe Aortic Stenosis
Device: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System
Device: Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System

The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart V...

Aortic Valve Stenosis
Device: Commercially available transcatheter aortic valve
Device: Portico transcatheter aortic valve

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated...

Active, not recruiting
Colorectal Cancer (CRC)
Drug: Regorafenib
Drug: Panitumumab

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and...

Active, not recruiting
Other: Combination Therapy placebo
Drug: Monotherapy ezetimibe

The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devic...

Active, not recruiting
Congestive Heart Failure
Device: SyncAV programmed ON
Device: Fixed AV delay

prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in...

Active, not recruiting
Cardiac Rhythm Disorder
Device: Aveir VR Leadless Pacemaker System

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hyperte...

Active, not recruiting
Cardiovascular Diseases
Procedure: Renal Angiogram
Device: Paradise Renal Denervation System

Trial sponsors

Abbott logo
Actelion Pharmaceuticals logo
Amgen logo
Medtronic logo
Medtronic logo
Pfizer logo
AtriCure logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems